Interpreting tuberculin skin tests in a population with a high prevalence of HIV, tuberculosis, and nonspecific tuberculin sensitivity

American Journal of Epidemiology

Volumn 171, Issue 9, 2010, Pages 1037-1045

  Dodd, Peter J ^a   Millington, Kerry A ^a   Ghani, Azra C ^a   Mutsvangwa, Junior ^c   Butterworth, Anthony E ^b,c   Lalvani, Ajit ^a   Corbett, Elizabeth L ^b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c BIOMEDICAL RESEARCH AND TRAINING INSTITUTE   (Zimbabwe)

Author keywords

enzyme linked immunosorbent assay; HIV; tuberculin test; tuberculosis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; TUBERCULOSTATIC AGENT;

BIOASSAY; CALIBRATION; DISEASE PREVALENCE; EPIDEMIOLOGY; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; MEDICINE; PUBLIC HEALTH; TESTING METHOD; TUBERCULOSIS; VACCINE;

ADOLESCENT; ADULT; ARTICLE; CALIBRATION; CHILD; CONTROLLED STUDY; CYTOKINE RELEASE; DIAGNOSTIC ERROR; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS; VALIDATION PROCESS; ZIMBABWE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; PREDICTION AND FORECASTING; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; RISK FACTOR; VIROLOGY;

HARARE [ZIMBABWE]; ZIMBABWE;

HUMAN IMMUNODEFICIENCY VIRUS;

ADOLESCENT; ADULT; CHILD; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HUMANS; LATENT TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TUBERCULIN TEST; ZIMBABWE;

EID: 77952297031     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq017     Document Type: Article

References (32)

1. World Health Organization. Global Tuberculosis Control: Epidemiology, Strategy, Financing. Geneva, Switzerland: World Health Organization; 2009. (WHO/HTM/TB/ 2009.411).
2. Churchyard GJ, Scano F, Grant AD, et al. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis. 2007;196(suppl 1):S52-S62.
3. Rieder HL. Methodological issues in the estimation of the tuberculosis problem from tuberculin surveys. Tuber Lung Dis. 1995;76(2):114-121.
4. Cobelens FG, Egwaga SM, van Ginkel T, et al. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis. 2006;43(5):634-639.
5. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149(3):177-184.
6. Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest. 2007;131(6): 1898-1906.
7. Karam F, Mbow F, Fletcher H, et al. Sensitivity of IFNgamma release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/ AIDS progression [electronic article]. PLoS One. 2008; 3(1):e1441.
8. Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med. 2007;175(7):737-742.
9. Lawn SD, Bangani N, Vogt M, et al. Utility of interferongamma ELISPOT assay responses in highly tuberculosisexposed patients with advanced HIV infection in South Africa [electronic article]. BMC Infect Dis. 2007;7:99.
10. Brock I, Ruhwald M, Lundgren B, et al. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test [electronic article]. Respir Res. 2006; 7:56.
11. Dheda K, Lalvani A, Miller RF, et al. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS. 2005;19(17):2038-2041.
12. Clark SA, Martin SL, Pozniak A, et al. Tuberculosis antigenspecific immune responses can be detected using enzymelinked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol. 2007;150(2):238-244.
13. Rangaka MX, Wilkinson KA, Seldon R, et al. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med. 2007;175(5): 514-520.
14. Bakir M, Dosanjh DP, Deeks JJ, et al. Use of T cell-based diagnosis of tuberculosis infection to optimize interpretation of tuberculin skin testing for child tuberculosis contacts. Clin Infect Dis. 2009;48(3):302-312.
15. Pai M, Dendukuri N, Wang L, et al. Improving the estimation of tuberculosis infection prevalence using T-cell-based assay and mixture models. Int J Tuberc Lung Dis. 2008;12(8): 895-902.
16. Corbett EL, Dauya E, Matambo R, et al. Uptake of workplace HIV counselling and testing: a cluster-randomised trial in Zimbabwe [electronic article]. PLoS Med. 2006;3(7):e238.
17. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med. 1999;159(1):15-21.
18. Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 2003;361(9364):1168-1173.
19. Corbett EL, Bandason T, Cheung YB, et al. Prevalent infectious tuberculosis in Harare, Zimbabwe: burden, risk factors and implications for control. Int J Tuberc Lung Dis. 2009; 13(10):1231-1237.
20. Sikhosana P. Family and Child Health Department, Executive Summary. Government of Zimbabwe; 1998.
21. Rieder HL. Epidemiologic Basis of Tuberculosis Control. 1st ed. Paris, France: International Union against Tuberculosis and Lung Disease; 1999.
22. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis. 2009;48(7):954-962.
23. Bakir M, Millington KA, Soysal A, et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med. 2008;149(11):777-787.
24. Diel R, Loddenkemper R, Meywald-Walter K, et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2008; 177(10):1164-1170.
25. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282(7):677-686.
26. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161(4 pt 2):S221-S247.
27. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons [electronic article]. Cochrane Database Syst Rev. 2004;(1):CD000171.
28. Edwards LB, Acquaviva FA, Livesay VT, et al. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis. 1969;99(4 suppl):S1-S132.
29. Arend SM, Thijsen SF, Leyten EM, et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med. 2007; 175(6):618-627.
30. Fisk TL, Hon HM, Lennox JL, et al. Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. AIDS. 2003;17(7): 1102-1104.
31. Egwaga SM, Cobelens FG, Muwinge H, et al. The impact of the HIV epidemic on tuberculosis transmission in Tanzania. AIDS. 2006;20(6):915-921.
32. Corbett EL, Marston B, Churchyard GJ, et al. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet. 2006;367(9514): 926-937.